This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Population Pharmacokinetics and Metabolomics of Theophylline in Preterm Infants

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2012 by Han-Suk Kim, Seoul National University Hospital.
Recruitment status was:  Enrolling by invitation
Seoul National University Bundang Hospital
Seoul National University Boramae Hospital
Korea University Anam Hospital
Information provided by (Responsible Party):
Han-Suk Kim, Seoul National University Hospital Identifier:
First received: January 9, 2012
Last updated: February 21, 2012
Last verified: February 2012
  1. Population pharmacokinetics : The purpose of this study is

    - to investigate the population pharmacokinetics of theophylline in premature Korean infants and to assess the influence of demographic and clinical covariates.

  2. Metabolomics : The purpose of this study are

    • to predict serum theophylline levels and to assess CYP1A2 activities in premature infants by analyzing urinary metabolites of theophylline
    • to examine which factors affect clearance of theophylline and CYP1A2 activity in premature infants

Apea of Prematurity

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Population Pharmacokinetics and Metabolomic Analysis of Aminopylline/Theophylline Drug Levels in Preterm Infants With Apnea of Prematurity

Resource links provided by NLM:

Further study details as provided by Han-Suk Kim, Seoul National University Hospital:

Estimated Enrollment: 110
Study Start Date: May 2010

Ages Eligible for Study:   up to 37 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Admitted to Neonatal Intensive Care Unit

Inclusion Criteria:

  • Inborn preterm infants (GA < 37 weeks)
  • Dx : Apnea of prematurity
  • Tx : Aminophylline / Theophylline
  • Informed consent of parents

Exclusion Criteria:

  • Major congenital anomaly
  • Expired within 72 hours
  • Proven secondary apnea
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Han-Suk Kim, Associate Professor & Director of Neonatal Intensive Care Unit, Seoul National University Hospital Identifier: NCT01509248     History of Changes
Other Study ID Numbers: TP-PopPK-Metabol
Study First Received: January 9, 2012
Last Updated: February 21, 2012

Keywords provided by Han-Suk Kim, Seoul National University Hospital:

Additional relevant MeSH terms:
Premature Birth
Obstetric Labor, Premature
Obstetric Labor Complications
Pregnancy Complications
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents processed this record on August 18, 2017